Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and Therapeutic Advances

被引:23
作者
Cruz-Ramon, Vania [1 ]
Chinchilla-Lopez, Paulina [1 ]
Ramirez-Perez, Oscar [1 ]
Mendez-Sanchez, Nahum [1 ]
机构
[1] Med Sur Clin & Fdn, Liver Res Unit, Puente Piedra 150, Mexico City 14050, DF, Mexico
关键词
Bile acids; NAFLD; Metabolism; Metabolic syndrome; NUCLEAR RECEPTOR; STEATOHEPATITIS; IDENTIFICATION; EPIDEMIOLOGY; METABOLISM; ALPHA;
D O I
10.5604/01.3001.0010.5498
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Nonalcoholic liver disease (NAFLD) is a major emerging health burden that is a common cause of illness and death worldwide. NAFLD can progress into nonalcoholic steatohepatitis (NASH) which is a severe form of liver disease characterized by inflammation and fibrosis. Further progression leads to cirrhosis, which predisposes patients to hepatocellular carcinoma or liver failure. The mechanism of the progression from simple steatosis to NASH is unclear. However, there are theories and hypothesis which support the link between disruption of the bile acids homeostasis and the progression of this disorder. Previous studies have been demonstrated that alterations of these pathways can lead to dysregulation of energy balance and an increase of liver inflammation and fibrosis. In this review, we summarized the current knowledge of the interaction between BA and the process related to the development of NAFLD, besides, the potential targets for novel therapies.
引用
收藏
页码:S58 / S67
页数:10
相关论文
共 50 条
[21]   A Review of the Therapeutic Potential of Ginseng and Its Bioactive Components in Nonalcoholic Fatty Liver Disease [J].
Hao, Liyuan ;
Li, Shenghao ;
Li, Caige ;
Zhang, Zhiqin ;
Hu, Xiaoyu ;
Yan, Huimin .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2025, 19 :83-96
[22]   Nonalcoholic Fatty Liver Disease [J].
Isaacs, Scott .
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2023, 52 (01) :149-164
[23]   Secondary bile acids improve risk prediction for non-invasive identification of mild liver fibrosis in nonalcoholic fatty liver disease [J].
Liu, A-Na ;
Xu, Cui-Fang ;
Liu, Ya-Ru ;
Sun, Dan-Qin ;
Jiang, Ling ;
Tang, Liang-Jie ;
Zhu, Pei-Wu ;
Chen, Sui-Dan ;
Liu, Wen-Yue ;
Wang, Xiao-Dong ;
Targher, Giovanni ;
Byrne, Christopher D. D. ;
Wong, Vincent Wai-Sun ;
Fu, Junfen ;
Su, Ming-Ming ;
Loomba, Rohit ;
Zheng, Ming-Hua ;
Ni, Yan .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (08) :872-885
[24]   Hypothyroidism and Nonalcoholic Fatty Liver Disease: Pathophysiological Associations and Therapeutic Implications [J].
Kizivat, Tomislav ;
Maric, Ivana ;
Mudri, Dunja ;
Curcic, Ines Bilic ;
Primorac, Dragan ;
Smolic, Martina .
JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2020, 8 (03) :347-353
[25]   Therapeutic modulation of the bile acid pool by Cyp8b1 knockdown protects against nonalcoholic fatty liver disease in mice [J].
Chevre, Raphael ;
Trigueros-Motos, Laia ;
Castano, David ;
Chua, Tricia ;
Corliano, Maria ;
Patankar, Jay V. ;
Sng, Lareina ;
Sim, Lauren ;
Juin, Tan Liang ;
Carissimo, Guillaume ;
Ng, Lisa F. P. ;
Yi, Cheryl Neo Jia ;
Eliathamby, Chelsea Chandani ;
Groen, Albert K. ;
Hayden, Michael R. ;
Singaraja, Roshni R. .
FASEB JOURNAL, 2018, 32 (07) :3792-3802
[26]   Nonalcoholic Fatty Liver Disease: Disease Burden and Disease Awareness [J].
Golabi, Pegah ;
Isakov, Vasily ;
Younossi, Zobair M. .
CLINICS IN LIVER DISEASE, 2023, 27 (02) :173-186
[27]   Advances in Pediatric Nonalcoholic Fatty Liver Disease [J].
Loomba, Rohit ;
Sirlin, Claude B. ;
Schwimmer, Jeffrey B. ;
Lavine, Joel E. .
HEPATOLOGY, 2009, 50 (04) :1282-1293
[28]   Recent advances in nonalcoholic fatty liver disease [J].
Cheung, Onpan ;
Sanyal, Arun J. .
CURRENT OPINION IN GASTROENTEROLOGY, 2009, 25 (03) :230-237
[29]   Advances in Pediatric Nonalcoholic Fatty Liver Disease [J].
Mencin, Ali A. ;
Lavine, Joel E. .
PEDIATRIC CLINICS OF NORTH AMERICA, 2011, 58 (06) :1375-+
[30]   Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease [J].
Lin, Chuan-Hao ;
Kohli, Rohit .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2018, 9